700 - The Pros, Cons, and Unknowns of Ozempic
Public Health On Call · Johns Hopkins Bloomberg School of Public Health
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Medications like Ozempic, Wegovy, and Mounjaro show lots of promise for treating obesity but scientists still don't understand exactly how they work. There's also a lack of data to show whether these medications are safe to take long term. Dr. Sameer Khan, a Johns Hopkins fellow in gasteroenterology, talks with Dr. Josh Sharfstein about what these medicines are and what they can do, the questions that remain, and why it's a challenge for clinicians to prescribe them and for patients to actually obtain them. Learn more about another one of our projects, the Expert Insights newsletter: publichealth.jhu.edu/subscribe